Nanobac Pharmaceuticals, Incorporated (NNBP)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Mar 3, 2026
Nanobac Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | 2002 |
|---|---|---|---|---|---|---|
Period Ending | Dec '07 Dec 31, 2007 | Dec '06 Dec 31, 2006 | Dec '05 Dec 31, 2005 | Dec '04 Dec 31, 2004 | Dec '03 Dec 31, 2003 | 2002 |
| Revenue | 0.02 | 0.23 | 0.66 | 0.36 | 0.48 | Upgrade
|
| Revenue Growth (YoY) | -92.17% | -65.73% | 83.28% | -25.78% | - | Upgrade
|
| Cost of Revenue | 0.01 | 0.08 | 0.23 | 0.1 | 0.33 | Upgrade
|
| Gross Profit | 0 | 0.15 | 0.43 | 0.26 | 0.15 | Upgrade
|
| Selling, General & Admin | 2.83 | 1.84 | 1.31 | 4.89 | 2.13 | Upgrade
|
| Research & Development | 1.15 | 1.99 | 1.19 | 2.25 | 0.54 | Upgrade
|
| Operating Expenses | 4.44 | 4.37 | 3.27 | 7.86 | 2.85 | Upgrade
|
| Operating Income | -4.43 | -4.23 | -2.84 | -7.6 | -2.7 | Upgrade
|
| Interest Expense | -0.19 | -0.2 | -0.07 | -0.25 | -0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.09 | 0.05 | -0.04 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0 | -0.74 | -0.61 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -4.54 | -4.37 | -3.69 | -8.46 | -2.76 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.02 | - | - | - | Upgrade
|
| Asset Writedown | - | -0.59 | - | - | - | Upgrade
|
| Legal Settlements | -0.48 | - | - | - | - | Upgrade
|
| Other Unusual Items | -1.56 | - | - | - | - | Upgrade
|
| Pretax Income | -6.58 | -4.97 | -3.69 | -8.46 | -2.76 | Upgrade
|
| Earnings From Continuing Operations | -6.58 | -4.97 | -3.69 | -8.46 | -2.76 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | -0.06 | -0.94 | Upgrade
|
| Net Income | -6.58 | -4.97 | -3.69 | -8.52 | -3.7 | Upgrade
|
| Net Income to Common | -6.58 | -4.97 | -3.69 | -8.52 | -3.7 | Upgrade
|
| Shares Outstanding (Basic) | 245 | 199 | 191 | 153 | 67 | Upgrade
|
| Shares Outstanding (Diluted) | 245 | 199 | 191 | 153 | 67 | Upgrade
|
| Shares Change (YoY) | 22.95% | 4.62% | 24.67% | 126.56% | 384.10% | Upgrade
|
| EPS (Basic) | -0.03 | -0.02 | -0.02 | -0.06 | -0.05 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.02 | -0.02 | -0.06 | -0.05 | Upgrade
|
| Free Cash Flow | -0.91 | -2.6 | -2.41 | -3.43 | -2.17 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.02 | -0.03 | Upgrade
|
| Gross Margin | 17.60% | 64.55% | 65.07% | 71.96% | 31.00% | Upgrade
|
| Operating Margin | -25162.08% | -1879.07% | -432.05% | -2120.87% | -559.26% | Upgrade
|
| Profit Margin | -37319.74% | -2209.53% | -561.41% | -2377.05% | -766.23% | Upgrade
|
| Free Cash Flow Margin | -5178.02% | -1154.07% | -366.31% | -957.84% | -450.17% | Upgrade
|
| EBITDA | -3.97 | -3.69 | -2.08 | -6.88 | -2.52 | Upgrade
|
| D&A For EBITDA | 0.46 | 0.54 | 0.76 | 0.72 | 0.18 | Upgrade
|
| EBIT | -4.43 | -4.23 | -2.84 | -7.6 | -2.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.